Literature DB >> 24052115

The diagnosis of chronic inflammatory demyelinating polyneuropathy: a Delphi-method approach.

Alain Créange1, Arnold Careyron.   

Abstract

The diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) is based on a set of clinical and neurophysiological parameters. However, in clinical practice, CIDP remains difficult to diagnose in atypical cases. In the present study, 32 experts from 22 centers (the French CIDP study group) were asked individually to score four typical, and seven atypical, CIDP observations (TOs and AOs, respectively) reported by other physicians, according to the Delphi method. The diagnoses of CIDP were confirmed by the group in 96.9 % of the TO and 60.1 % of the AO (p < 0.0001). There was a positive correlation between the consensus of CIDP diagnosis and the demyelinating features (r = 0.82, p < 0.004). The European CIDP classification was used in 28.3 % of the TOs and 18.2 % of the AOs (p < 0.002). The French CIDP study group diagnostic strategy was used in 90 % of the TOs and 61 % of the AOs (p < 0.0001). In 3 % of the TOs and 21.6 % of the AOs, the experts had difficulty determining a final diagnosis due to a lack of information. This study shows that a set of criteria and a diagnostic strategy are not sufficient to reach a consensus for the diagnosis of atypical CIDP in clinical practice.

Entities:  

Mesh:

Year:  2013        PMID: 24052115     DOI: 10.1007/s00415-013-7100-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy.

Authors:  Pariwat Thaisetthawatkul; Eric L Logigian; David N Herrmann
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

2.  Chronic inflammatory polyradiculoneuropathy.

Authors:  P J Dyck; A C Lais; M Ohta; J A Bastron; H Okazaki; R V Groover
Journal:  Mayo Clin Proc       Date:  1975-11       Impact factor: 7.616

Review 3.  Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J-M Vallat
Journal:  Postgrad Med J       Date:  2008-07       Impact factor: 2.401

4.  Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.

Authors:  K J Smith; P A Felts; G R John
Journal:  Brain       Date:  2000-01       Impact factor: 13.501

5.  Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.

Authors:  L Ruts; J Drenthen; B C Jacobs; P A van Doorn
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

6.  Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients.

Authors:  Rizwan U Haq; William W Pendlebury; Timothy J Fries; Rup Tandan
Journal:  Muscle Nerve       Date:  2003-04       Impact factor: 3.217

7.  Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia.

Authors:  M Sinnreich; C J Klein; J R Daube; J Engelstad; R J Spinner; P J B Dyck
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

8.  Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  Paul Magda; Norman Latov; Thomas H Brannagan; Louis H Weimer; Russell L Chin; Howard W Sander
Journal:  Arch Neurol       Date:  2003-12

9.  Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.

Authors:  C L Koski; M Baumgarten; L S Magder; R J Barohn; J Goldstein; M Graves; K Gorson; A F Hahn; R A C Hughes; J Katz; R A Lewis; G J Parry; P van Doorn; D R Cornblath
Journal:  J Neurol Sci       Date:  2008-12-16       Impact factor: 3.181

10.  Sensory CIDP presenting as cryptogenic sensory polyneuropathy.

Authors:  Russell L Chin; Norman Latov; Howard W Sander; Arthur P Hays; Sidney E Croul; Paul Magda; Thomas H Brannagan
Journal:  J Peripher Nerv Syst       Date:  2004-09       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.